Table 1.

Examples of studies on nanoconjuagtes of poorly water-soluble drugs for therapeutics.

Poorly Water-Soluble Drugs	Approaches	Key Results	References
SN38 (the active metabolite of camptothecin)	Multi-arm	Enhanced drug solubility. Significant preclinical therapeutic improvement and a longer half-life of the drug.	[46,47]
Ursolic acid and 10-hydroxycamptothecin		Effective cellular uptake. Higher survival rate of tumour-bearing mice.	[48]
Docetaxel	Redox/enzyme responsive	Triggering dual-responsive drug release. Facilitating drug release by an on/off switch in the desired environment.	[49,50]
Doxorubicin	Multiple targeting	Synergistic targeting effect.	[51]
Paclitaxel Doxorubicin Cytarabine	Poorly water-soluble drugs as hydrophobic segments in the core-shell structure	High drug loading.	[52,53,54]
Fucoidan Paclitaxel Curcumin	The combination use of a hydrophilic therapeutic agent	Dual functions.	[55,56]
Docetaxel	Hydrophobic drug-spacer-hydrophilic drug conjugates	Co-delivery of anticancer drugs.	[57]
Chlorambucil	Hydrophobic drug-hydrophilic drug conjugates	Excellent anticancer activity.	[58]
Isradipine Prednisolone	Solid dispersion	Improve drug bioavailability.	[59,60]